SCHEMBL24673552

SCHEMBL24673552

CC(C)CNC(=O)NCCOCCOCCNC(=O)C(C)S

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
EPHX1 P07099 2/20 0.45
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
PTGS2 P35354 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
CA2 P00918 1/20 0.35
HSD17B10 Q99714 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
MMP1 P03956 1/20 0.33
MMP8 P22894 1/20 0.33
EPHX2 P34913 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HDAC3 O15379 2/20 0.32
HDAC1 Q13547 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21106046 0.87 KMT2A (0.56) MEN1KMT2AEPHX1MAPTLMNA
SCHEMBL25729276 0.85 KMT2A (0.50) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL26407268 0.84 EPHX1 (0.47) MEN1KMT2AEPHX1MAPTLMNA
SCHEMBL22837658 0.82 EPHX1 (0.49) MEN1KMT2AEPHX1MAPTLMNA
SCHEMBL24673081 0.82 EPHX1 (0.49) MEN1KMT2AEPHX1MAPTALDH1A1
SCHEMBL25700630 0.81 EPHX1 (0.45) MEN1KMT2AEPHX1MAPTLMNA
SCHEMBL23695977 0.79 EPHX1 (0.50) MEN1KMT2AEPHX1MAPTALDH1A1
SCHEMBL24673439 0.79 MEN1 (0.54) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL23945307 0.79 EPHX1 (0.50) MEN1KMT2AEPHX1MAPTLMNA
SCHEMBL25477056 0.79 MEN1 (0.54) MEN1KMT2AMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-18 US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885EPHX1 1684/4885
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 MEN1 1517/4885KMT2A 310/4885EPHX1 2979/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885EPHX1 1684/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885EPHX1 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.